Discontinued long-term use of infliximab correlated with lower rates of maintained remission in patients with ulcerative colitis, according to research published in The Lancet Gastroenterology and Hepatology.

“Infliximab is an anti-tumor necrosis factor antibody and is one of the most widely used therapies in patients who are corticosteroid-refractory. Maintenance administration every 8-weeks is the standard protocol because of the frequent development of antibodies to infliximab on episodic treatment,” Taku Kobayashi, MD, Center for Advanced IBD Research and Treatment at Kitasato

Full Article: https://www.healio.com/news/gastroenterology/20210423/infliximab-discontinuation-links-to-relapse-in-patients-with-ulcerative-colitis